220 related articles for article (PubMed ID: 15972966)
21. Decreased expression of thyrotropin receptor gene suggests a high-risk subgroup for oncocytic adenoma.
Mirebeau-Prunier D; Guyétant S; Rodien P; Franc B; Baris O; Rohmer V; Reynier P; Tourmen Y; Malthièry Y; Savagner F
Eur J Endocrinol; 2004 Mar; 150(3):269-76. PubMed ID: 15012610
[TBL] [Abstract][Full Text] [Related]
22. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.
Eberhardt NL; Grebe SK; McIver B; Reddi HV
Mol Cell Endocrinol; 2010 May; 321(1):50-6. PubMed ID: 19883731
[TBL] [Abstract][Full Text] [Related]
23. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
24. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value.
Sahin M; Allard BL; Yates M; Powell JG; Wang XL; Hay ID; Zhao Y; Goellner JR; Sebo TJ; Grebe SK; Eberhardt NL; McIver B
J Clin Endocrinol Metab; 2005 Jan; 90(1):463-8. PubMed ID: 15483076
[TBL] [Abstract][Full Text] [Related]
25. Detection of PAX8-PPARG fusion transcripts in archival thyroid carcinoma samples by conventional RT-PCR.
Klemke M; Drieschner N; Belge G; Burchardt K; Junker K; Bullerdiek J
Genes Chromosomes Cancer; 2012 Apr; 51(4):402-8. PubMed ID: 22179975
[TBL] [Abstract][Full Text] [Related]
26. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma.
McIver B; Grebe SK; Eberhardt NL
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):221-34. PubMed ID: 15379724
[TBL] [Abstract][Full Text] [Related]
27. [Oncogenes and thyroid tumors].
Lacroix L; Soria JC; Bidart JM; Schlumberger M
Bull Cancer; 2005 Jan; 92(1):37-43. PubMed ID: 15689324
[TBL] [Abstract][Full Text] [Related]
28. Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings.
Jeong SH; Hong HS; Kwak JJ; Lee EH
J Endocrinol Invest; 2015 Aug; 38(8):849-57. PubMed ID: 25999051
[TBL] [Abstract][Full Text] [Related]
29. [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
Maciel RM; Kimura ET; Cerutti JM
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):691-700. PubMed ID: 16444351
[TBL] [Abstract][Full Text] [Related]
30. Predominant
Lee YA; Im SW; Jung KC; Chung EJ; Shin CH; Kim JI; Park YJ
Thyroid; 2020 Aug; 30(8):1120-1131. PubMed ID: 32228164
[No Abstract] [Full Text] [Related]
31. Association between Pax8-PPARandgamma;1 Rearrangement and Follicular Thyroid Cancer: a Meta-Analysis.
Li HY; Xie ZH; Xu CH; Pu ML; Chen ZY; Yu M; Wang HS; Zhou CM; Pu CY; Liu W
Asian Pac J Cancer Prev; 2016; 17(9):4247-4250. PubMed ID: 27797226
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis.
Algeciras-Schimnich A; Milosevic D; McIver B; Flynn H; Reddi HV; Eberhardt NL; Grebe SK
Clin Chem; 2010 Mar; 56(3):391-8. PubMed ID: 20056739
[TBL] [Abstract][Full Text] [Related]
33. Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.
Zhang Y; Yu J; Grachtchouk V; Qin T; Lumeng CN; Sartor MA; Koenig RJ
Oncotarget; 2017 Jan; 8(4):5761-5773. PubMed ID: 28008156
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.
Dobson ME; Diallo-Krou E; Grachtchouk V; Yu J; Colby LA; Wilkinson JE; Giordano TJ; Koenig RJ
Endocrinology; 2011 Nov; 152(11):4455-65. PubMed ID: 21952241
[TBL] [Abstract][Full Text] [Related]
35. PAX8PPARgamma stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line.
Espadinha C; Cavaco BM; Leite V
Thyroid; 2007 Jun; 17(6):497-509. PubMed ID: 17614769
[TBL] [Abstract][Full Text] [Related]
36. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.
Dwight T; Thoppe SR; Foukakis T; Lui WO; Wallin G; Höög A; Frisk T; Larsson C; Zedenius J
J Clin Endocrinol Metab; 2003 Sep; 88(9):4440-5. PubMed ID: 12970322
[TBL] [Abstract][Full Text] [Related]
37. The expression of PAX8-PPARgamma rearrangements is not specific to follicular thyroid carcinoma.
Nakabashi CC; Guimarães GS; Michaluart P; Ward LS; Cerutti JM; Maciel RM
Clin Endocrinol (Oxf); 2004 Aug; 61(2):280-2. PubMed ID: 15272927
[No Abstract] [Full Text] [Related]
38. Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms.
Chia WK; Sharifah NA; Reena RM; Zubaidah Z; Clarence-Ko CH; Rohaizak M; Naqiyah I; Srijit D; Hisham AN; Asmiati A; Rafie MK
Cancer Genet Cytogenet; 2010 Jan; 196(1):7-13. PubMed ID: 19963130
[TBL] [Abstract][Full Text] [Related]
39. Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein.
Zhang Y; Yu J; Lee C; Xu B; Sartor MA; Koenig RJ
Oncotarget; 2015 Dec; 6(38):40418-32. PubMed ID: 26595524
[TBL] [Abstract][Full Text] [Related]
40. The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.
Reddi HV; McIver B; Grebe SK; Eberhardt NL
Endocrinology; 2007 Mar; 148(3):932-5. PubMed ID: 16946003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
